<DOC>
	<DOCNO>NCT00067743</DOCNO>
	<brief_summary>This multicenter , open-label study adult subject Type 1 Complex Regional Pain Syndrome . Subjects diagnose unilateral Type 1 CRPS enrol sequentially receive CC-5013 10 mg/day orally . For subject study consist two phase : Pre-treatment phase ( 1 wk ) treatment phase ( 12 wks )</brief_summary>
	<brief_title>A Study CC-5013 Treatment Complex Regional Pain Syndrome ( CRPS )</brief_title>
	<detailed_description>Once subject completes 12 week treatment phase subject eligible continue trial . Subjects may continue benefit obtain .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Somatoform Disorders</mesh_term>
	<mesh_term>Complex Regional Pain Syndromes</mesh_term>
	<mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>A diagnosis Type 1 CRPS define modify International Association Study Pain criterion ( App 1 ) least one year duration Unilateral involvement distal hand foot without proximal speed must present . The severely affected limb designate index limb . CRPS pain severity score index limb 4 great 11point ( 010 ) NRS ( Appendix I ) . Opioid analgesic , nonopioid analgesic , nonsteroidal antiinflammatory drug , anticonvulsant antidepressant drug may continue provided subject stable dos least four week prior Treatment phase . Understand voluntarily sign informed consent form Able adhere study visit schedule protocol requirement Women childbearing potential ( WCBP ) must negative serum urine pregnancy test within 7 day start study drug . In addition , sexually active WCBP must agree use adequate contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) study drug . WCBP must agree pregnancy test every 4 week study drug . The average CRPS pain severity score index limb end PreTreatment Phase I ( must 4 great ) 2 daily score week must within +/ one point average . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Prior treatment CC5013 Prior development allergic reaction/hypersensitivity take thalidomide . Prior development moderate sever rash desquamation take thalidomide . Pregnant lactating female . Active litigation , compensation disability issue relate CRPS . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Use experimental drug therapy within 28 day treatment phase .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Pain</keyword>
	<keyword>Pain syndrome</keyword>
	<keyword>Reflex sympathetic dystrophy</keyword>
	<keyword>CC-5013</keyword>
	<keyword>CC5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Celgene</keyword>
	<keyword>CRPS</keyword>
</DOC>